Publié le Laisser un commentaire

Cellular Senescence Prevents Unlearning in Some Male Mice

In Aging Cell, researchers have established a link between cellular senescence and cognitive decline in unmodified male mice.

Resilience versus decline

The authors begin their paper by noting that cognitive decline in older people varies greatly. Some people suffer serious cognitive defects; other people are scarcely impacted at all [1]. The researchers have developed an automated tool called PhenoTyper to measure this in unmodified male Black 6 mice, establishing a benchmark set at 5 to 7 months old and using it to classify older mice as either intact or impaired [2]. They previously used this benchmark to ascertain that some mice remain fully functioning throughout their lives while others suffer serious cognitive decline [3].

This decline has nothing to do with Alzheimer’s, which wild-type mice cannot get. Instead, the researchers point to reactive gliosis, which, under normal circumstances, is the brain’s response to injury [4]. Sustained, chronic inflammation in aging is known as inflammaging, and sustained reactive gliosis is this process in the brain. The same compounds that are responsible for systemic inflammaging, such as the senescence-associated secretory phenotype (SASP), occur in the brain as well, and previous work has found that removing these cells leads to cognitive benefits [5].

However, these researchers hold that such previous work did not adequately distinguish between cognitively impaired and intact mice. Therefore, they performed an experiment of their own, attempting to more thoroughly document the relationship between brain senescence and cognitive decline.

Teaching old mice new tricks

For their first experiment, the researchers used their PhenoTyper system to assess the capabilities of their mice. In this experiment, mice were taught for 50 hours that they must enter the leftmost hole of a three-hole setup in order to receive food pellets; for another 40 hours, however, they had to use the rightmost hole instead (“reversal learning”).

In learning the initial hole, young (6 months) mice and old (22 to 24 months) mice performed similarly well. However, in the reversal learning task, there was an immense amount of difference between the two groups; the older mice’s performance was bimodal, with some older mice completely failing to unlearn what they had learned.

These dramatic differences within the aged group were not related to the total distance moved by the mice, nor were they related to changes in circadian rhythms (this test was performed during the dark hours in which mice are most active). They also only applied to male mice; female mice did not have a similarly sharp stratification.

The researchers then examined the differences between these stratified groups. They found substantial and stark differences in both morphology and in biochemistry. Microglial activity was greatly increased in the impaired group, while the intact group was indistinguishable in this area from younger mice. Some biomarkers of reactive gliosis were moderately increased in the intact group, but all of them were far more elevated in the impaired group. These researchers, therefore, hold that they have found a distinct phenotype of neurological impairment.

This was linked to biomarkers of cellular senescence. Interestingly, the p16 senescence biomarker, which was significantly more elevated in intact older mice compared to young mice, was only slightly more elevated in the impaired group. p21 was nearly the same in both older groups and elevated compared to younger mice. However, other biomarkers were significantly different. The interleukin IL-6 was notably upregulated only in the impaired group, as was the key senescence marker SA-β-gal.

Senolytics appear to help

The researchers then administered the well-known senolytic combination of dasatinib and quercetin (D+Q) to 22-month-old mice and performed cognitive tests at 24 months. Nearly all the older animals given the senolytic were considered cognitively intact mice, with very few failing the reversal learning task. Their senescent cell biomarkers were similarly reduced to those of intact mice, with IL-6 reaching approximately the level of young mice; similar beneifits were found in microglial morphology and biochemistry. Once again, these findings only applied to males.

The researchers surmise that such sex-related differences may also apply to human beings. Additionally, this work applies specifically to ‘normal’ cognitive decline that may not be directly related to proteostasis diseases such as Alzheimer’s. However, if a relevant human population can be identified, a senolytic or senomorphic regimen may allow them to retain their cognitive abilities.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future.

Literature

[1] Marron, M. M., Wojczynski, M. K., Minster, R. L., Boudreau, R. M., Sebastiani, P., Cosentino, S., … & Long Life Family Study. (2019). Heterogeneity of healthy aging: comparing long-lived families across five healthy aging phenotypes of blood pressure, memory, pulmonary function, grip strength, and metabolism. Geroscience, 41, 383-393.

[2] Baier, M. P., Nagaraja, R. Y., Yarbrough, H. P., Owen, D. B., Masingale, A. M., Ranjit, R., … & Logan, S. (2022). Selective ablation of Sod2 in astrocytes induces sex-specific effects on cognitive function, d-serine availability, and astrogliosis. Journal of Neuroscience, 42(31), 5992-6006.

[3] Logan, S., Baier, M. P., Owen, D. B., Peasari, J., Jones, K. L., Ranjit, R., … & Sonntag, W. E. (2023). Cognitive heterogeneity reveals molecular signatures of age-related impairment. PNAS nexus, 2(4), pgad101.

[4] Sochocka, M., Diniz, B. S., & Leszek, J. (2017). Inflammatory response in the CNS: friend or foe?. Molecular neurobiology, 54, 8071-8089.

[5] Ogrodnik, M., Evans, S. A., Fielder, E., Victorelli, S., Kruger, P., Salmonowicz, H., … & Jurk, D. (2021). Whole‐body senescent cell clearance alleviates age‐related brain inflammation and cognitive impairment in mice. Aging cell, 20(2), e13296.

Publié le Laisser un commentaire

Human Exposome Project Explores Environmental Disease Causes

Recent research confirms the relatively minor role that genetics plays in our health, with the ‘exposome’, defined as the totality of exposures individuals experience over their lives affecting their health, responsible for 10 times more variation in mortality risk than genetic predisposition [1].

A paper published in Nature Medicine today, ‘Cities, communities and clinics can be testbeds for human exposome and aging research’ [2], sets out ways to start measuring how humans are affected by the exposome and furnish long-overdue evidence to design environments that enhance healthy life expectancy while reducing health and wellbeing inequalities.

The publication of the paper coincides with a tipping point for an international movement behind the ‘Human Exposome Project’, a generation on from the Human Genome Project, to understand how external exposures (including social, behavioural and geo-physical factors) and their interaction with internal factors (such as genetics and physiology), affect an individual’s health and overall resilience.

The Exposome Moonshot Forum is meeting for the first time in Washington, DC, 12-15 May 2025, to launch an unprecedented international scientific endeavour to map the combined impact of environmental factors that impact human health from conception to death.

Specific environmental factors can activate pathological pathways that contribute to disease and accelerate aging. The ability to capture, analyse and link individual data outside the medical record can show how external exposures affect a person’s health across their lifetime. These interactions can now be much better understood at an individual level and traced with unprecedented precision using artificial intelligence, representing a significant leap forward in determining the impact of the exposome at an aggregated, population health level.

This work is crucial to define new ways to address the chronic disease epidemic and ageing demographic now creating an economic drag in many nations around the world. The evidence will shape more effective public health interventions urgently needed to shift investment and policy away from an unsustainable healthcare model to one more rooted in prevention.

Tina Woods, steering committee member, Exposome Moonshot Forum; CEO, Collider Health; executive director of the International Institute of Longevity, and corresponding author says: ‘The time for the Human Exposome Project has come and I am excited to be participate in the Exposome Moonshot Forum to move it from concept to reality. We need to measure the exposome to demonstrate the return on investing in health and incentivising prevention.’

Professor David Furman, Buck Institute for Research on Aging, director of the Stanford 1000 Immunomes Project, steering committee member, Exposome Moonshot Forum, and corresponding author says: ‘At a time of increasing environmental threats to human health such as air pollution and microplastics, we have the technologies like applied artificial intelligence to help us to unravel the complex interactions between environment, immunity and health at an individual level that can be aggregated up to get a true picture of the relative impact drivers of population health’.

Professor Nic Palmarini, director of the National Innovation Centre for Ageing, and author, says: ‘We have the technologies and tools to understand the human exposome with clinics, communities and cities acting as ideal real-world testbeds to understand what solutions will promote healthier behaviours and ultimately, outcomes.’

Buck Institute

The mission of the Buck Institute is to end the threat of age-related disease for this and future generations. It is the first biomedical research institution devoted solely to research on ageing revolving around our commitment to helping people live better longer.

Media contact:

Kris Rebillot, Senior Director of Communications

415-209-2080

krebillot@buckinstitute.org

National Innovation Centre for Ageing

The UK’s National Innovation Centre for Ageing is a world-leading organisation to help co-develop and bring to market products and services which create a world in which we people live better, for longer.

Media contact:

Lynne Corner

+44 (0) 7713 245780

lynne.corner@ncl.ac.uk

International Institute for Longevity

The International Institute of Longevity (IIOL) is focused on driving global excellence, industry standards and best practice in the real-world application of longevity science into ‘longevity clinics’ as well as scientific and medical innovation to extend human healthspan, resilience and flourishing in the wider context of corporate and urban health and wellness.

Media contact:

Tina Woods

+44 (0) 7808 402032

t.woods@l-institute.com

Exposome Moonshot Forum

The Exposome Moonshot Forum on 12-15 May in Washington DC is intended to define and accelerate the future of the Human Exposome Project (HEP). The central aim of the Forum is to identify the resources, policies, and collaboration necessary to drive the successful implementation of the HEP, ensuring longevity and impact. Outcomes will centre around:

Defining clear, actionable steps toward the scalable implementation of the HEP.
Building consensus on the essential policy changes needed to support and expand research.
Establishing long-term collaborative partnerships that will bring together diverse sectors, including academia, industry, government agencies, and non-profit organizations, and divert critical funds toward this project and toward successful integration of active working groups

Media contact:

Eliza Cole, Communications Specialist

ecole28@jh.edu

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future.

Literature

[1] Argentieri, M.A., Amin, N., Nevado-Holgado, A.J. et al. Integrating the environmental and genetic architectures of aging and mortality. Nat Med (2025).
[2] Woods, T., Furman D., Palmarini N. et al. Cities, communities and clinics can be testbeds for human exposome and aging research. Nat Med (2025).

Publié le Laisser un commentaire

How Life Expectancy Has Changed in Europe

A recent country-level analysis of life expectancy among several European nations shows changes in life expectancy trends and how well-designed national policies can reduce or minimize exposure to risk factors, thus improving life expectancy [1].

Slowdown in life expectancy increase

Life expectancy has grown in high-income countries since at least 1900, except during the two World Wars and the 1918 influenza pandemic [2]. However, the speed of the growth differed; for example, since 2011, Europe’s trend towards life expectancy increases was reduced, and this was followed by a decline in life expectancy in most European countries due to the COVID-19 pandemic [3, 4].

The authors of this recent study used the data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 to compare changes in life expectancy and exposure to risk factors in the 16 founding European Economic Area countries and four UK nations.

The life expectancy at birth was defined as “the mean number of years that a newborn infant could expect to live, if he or she were to pass through life exposed to the sex-specific and age-specific death rates prevailing at the time of his or her birth, in a given country.”

They compared periods of 1990 to 2011 (pre-slowdown in life expectancy), 2011 to 2019 (slowdown in life expectancy to pre-COVID-19 pandemic), and 2019 to 2021 (COVID-19 pandemic).

Country-level analysis

When analyzed separately, all countries showed improved life expectancy from 1990 to 2011 and 2011 to 2019; however, the rate varied. Confirming the observations of bulk data analysis reported previously, the rate of life expectancy improvement was higher in the 1990-to-2011 period than the 2011-to-2019 period.

Norway was the only exception from that observation. In Norway, the trend of life expectancy increased more during the 2011-to-2019 period compared to the 1990-to-2011 period.

During the COVID-19 pandemic and post-pandemic period, all countries but Ireland, Iceland, Sweden, Norway, Denmark, and Belgium experienced an absolute fall in life expectancy, with Greece and England observing the most significant decrease.

Cardiovascular diseases, cancers, and COVID-19

The life expectancy improvements seen in the 1990-to-2011 period stem from improvements related to causes of death attributed to cardiovascular diseases and neoplasms, which are tissue masses that result from abnormal growth, whether benign or cancerous.

Unsurprisingly, the decrease in life expectancy in years 2019–21 can be attributed to the deaths from respiratory infections and other COVID-19-related health problems. However, before the COVID-19 pandemic period, reductions in improvements in life expectancy were primarily driven by cardiovascular diseases.

The researchers also made an interesting observation: “among the studied countries, those with the greatest slowdown in life expectancy improvements before the COVID-19 pandemic were generally most severely affected by COVID-19 and had some of the largest decreases in life expectancy in 2019-21.”

Avoiding risk

The researchers analyzed risk factors, attributed to different causes of death, for both sexes in all countries combined in 2019. The top three risk factors for cardiovascular disease were high systolic blood pressure, dietary risks, and high LDL cholesterol. For neoplasms, the top risk factors included tobacco smoke, dietary risks, and occupational risks.

The levels of different risk factors changed with time, such as exposure to tobacco smoke; even though it is still a high population risk, it has decreased over time. On the other hand, BMI has increased in all countries, and dietary risks, high alcohol use, and low physical activity remain high in most.

The authors also point to high LDL cholesterol and systolic blood pressure, which declined until before 2011; however, this trend reversed after 2011 in many countries.

The danger of a risk factor varies by the time between exposure to it and the start of the disease that it causes, the length of exposure, and its interactions with other risk factors. Unfortunately, this dataset doesn’t provide some of that information.

Funding healthcare

Following their analysis, the authors discuss governmental policies and their impact on life expectancy. For example, they mention national fiscal and healthcare policies that impact the population’s life expectancy, especially for people in the worst socioeconomic situations.

An example of policies aimed at increase access to healthcare are Belgian, French, and Norwegian national policies, which, in recent years, have focused on increasing cancer diagnosis and treatment. The authors hold that these policies improved life expectancy related to neoplasms between 1990 and 2019. Additionally, some research has suggested that funding cuts to health, social care, and welfare since 2010 contributed to the slowdown in life expectancy improvement [5, 6].

Diet and physical activity are the foundation of health and longevity

Diagnosis and treatment happen after a person suffers from a disease. Preventing diseases from occurring through proper diet and physical activity might be more effective at increasing life expectancy.

The authors give examples of how healthy food consumption can be influenced by effective policy. An example is Norway, which had implemented a sugar tax as early as 1922. Similarly, starting in the 1980s, the Norwegian government talked with the industry about reducing the amount of salt in food products. This was complemented by Norway’s ‘Action Plan on Nutrition 2007–2011’, which, apart from education, also focused on other nutritional aspects, such as increasing focus on nutrition in a health care setting.

This broader approach has proven more effective than focusing only on education and voluntary dietary changes. Apart from diet, physical activity is the cornerstone of health and reducing premature mortality. Unfortunately, accordingly to this analysis, at the population level, there were no improvements in the levels of even low physical activity across the studied countries. The authors believe that systematic strategies and incentives are necessary to change that.

Ultimately, the authors intend for policymakers to utilize this analysis as a guide to reverse their countries’ slowdown in life expectancy improvement. They also hold that countries that implement successful policies can be used as examples for others to follow.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future.

Literature

[1] GBD 2021 Europe Life Expectancy Collaborators (2025). Changing life expectancy in European countries 1990-2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021. The Lancet. Public health, 10(3), e172–e188.

[2] Roser M. (2020) The Spanish flu: the global impact of the largest influenza pandemic in history. https://ourworldindata.org/spanish-flu-largest-influenza-pandemic-in-history

[3] Raleigh VS. (2019) Trends in life expectancy in EU and other OECD countries. OECD Health Working Papers 108. https://www.oecd.org/en/publications/trends-in-life-expectancy-ineu-and-other-oecd-countries_223159ab-en.html

[4] Organisation for Economic Co-operation and Development, EU. (2018) Health at a glance: Europe 2018: state of health in the EU Cycle. https://www.oecd.org/en/publications/health-at-aglance-europe-2018_health_glance_eur-2018-en.html

[5] Alexiou, A., Fahy, K., Mason, K., Bennett, D., Brown, H., Bambra, C., Taylor-Robinson, D., & Barr, B. (2021). Local government funding and life expectancy in England: a longitudinal ecological study. The Lancet. Public health, 6(9), e641–e647.

[6] McCartney, G., McMaster, R., Popham, F., Dundas, R., & Walsh, D. (2022). Is austerity a cause of slower improvements in mortality in high-income countries? A panel analysis. Social science & medicine (1982), 313, 115397.